학술논문

Pituitary MRI in Cushing's disease ‐ an update.
Document Type
Article
Source
Journal of Neuroendocrinology. Aug2022, Vol. 34 Issue 8, p1-8. 8p.
Subject
*CUSHING'S syndrome
*MAGNETIC resonance imaging
*POSITRON emission tomography
*HYPOPITUITARISM
Language
ISSN
0953-8194
Abstract
Pituitary MRI is essential in the diagnosis of ACTH‐dependent Cushing's syndrome, but its results are inconsistent. The demonstration of a sellar image compatible with the diagnosis of corticotropinoma varies from 40% to 90%, depending on the centre where the imaging is performed. In fact, the expertise of the neuroradiologist, use of a Tesla 3.0 MRI and choice of sequences are fundamental. The T2 and 3D gradient echo sequences after gadolinium injection are the most informative and today allow the detection of macro‐ and microadenomas in almost all cases. The diagnosis of numerous picoadenomas (<3–4 mm) is more challenging. The 2D and 3D spin echo or delayed T1 SE or FLAIR sequences after gadolinium can be used as a complement or to confirm a suspicious image. Characterization of corticotropinomas remains problematic. However, the correct assessment of so‐called incidentalomas by recognizing artifacts, anatomical variants and frequent Rathke's cleft cysts eliminates around 90% of the incidentalomas that mimic pituitary adenomas, as repetitively reported in the literature. For the time being, there is reason to believe that hybrid imaging combining PET and MRI such as 11C‐methionine PET coregistered with volumetric MRI will solve the diagnosis of corticotropinomas in the near future. [ABSTRACT FROM AUTHOR]